Loading…
Loading…
Amova Asset Management Americas Inc. cut its position in shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB) by 9.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,037,987 shares of the biotechnology company's stock after selling 770,593 shares during the
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.36, indicating a -5.56% shift from the previous trading day.
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
MENLO PARK, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p. m. Eastern Time (1:30 p. m.
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.49, signifying a -4.49% move from its prior day's close.
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.66, moving 1.19% from the previous trading session.
Pacific Biosciences of California (PACB) closed at $1.68 in the latest trading session, marking a -2.89% move from the prior day.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for PACB and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.